Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) – Stock analysts at Cantor Fitzgerald raised their FY2019 earnings estimates for shares of Spring Bank Pharmaceuticals in a research note issued on Tuesday, March 12th. Cantor Fitzgerald analyst E. Piros now expects that the company will earn ($1.90) per share for the year, up from their prior estimate of ($2.40). Cantor Fitzgerald has a “Buy” rating and a $34.00 price objective on the stock.
Spring Bank Pharmaceuticals (NASDAQ:SBPH) last issued its quarterly earnings data on Monday, March 11th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.17.
Shares of Spring Bank Pharmaceuticals stock opened at $10.44 on Friday. The firm has a market capitalization of $172.09 million, a PE ratio of -5.58 and a beta of 0.80. Spring Bank Pharmaceuticals has a 12 month low of $8.14 and a 12 month high of $15.73.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Northern Trust Corp increased its stake in Spring Bank Pharmaceuticals by 0.9% in the 4th quarter. Northern Trust Corp now owns 171,750 shares of the company’s stock valued at $1,785,000 after buying an additional 1,507 shares during the period. Bank of New York Mellon Corp increased its stake in Spring Bank Pharmaceuticals by 5.9% in the 4th quarter. Bank of New York Mellon Corp now owns 43,789 shares of the company’s stock valued at $454,000 after buying an additional 2,430 shares during the period. Rhumbline Advisers increased its stake in Spring Bank Pharmaceuticals by 65.3% in the 4th quarter. Rhumbline Advisers now owns 16,771 shares of the company’s stock valued at $174,000 after buying an additional 6,623 shares during the period. Geode Capital Management LLC increased its stake in Spring Bank Pharmaceuticals by 8.7% in the 4th quarter. Geode Capital Management LLC now owns 116,861 shares of the company’s stock valued at $1,214,000 after buying an additional 9,398 shares during the period. Finally, Blair William & Co. IL acquired a new position in Spring Bank Pharmaceuticals in the 3rd quarter valued at $123,000. 43.18% of the stock is currently owned by institutional investors.
Spring Bank Pharmaceuticals Company Profile
Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV).
Read More: Leveraged Buyout (LBO) Explained
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.